Zymeworks cuts deal to buy Theravance for $929m in cash
In a second M&A announcement today, Zymeworks has reached an agreement to buy Theravance Biopharma, claiming rights to Yupelri, a treatment for chronic obstructive pulmonary disease (COPD). The all-cash deal, valued at $929 million, gives Canada-based …